Sold as Ketek. Every FDA application for this active ingredient.
As of Nov 13, 2026, FDA lists 1 application for Telithromycin (sold as Ketek), first approved Apr 1, 2004, with 1 new use approved and 0 published complete response letters.
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Apr 1, 2004 | KetekNDA 21144 ยท New molecular entity | Sanofi Aventis US | 13 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number. Drugs@FDA
